A
ACELYRIN Inc
NASDAQ:SLRN
ACELYRIN Inc
NASDAQ:SLRN
Price:
2.27
USD
Market Closed
Market Cap:
$229.2m
Relative Value
There is not enough data to reliably calculate the relative value of SLRN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SLRN
Relative Value
Base Case
Not Available
A
Multiples Across Competitors
SLRN Competitors Multiples
ACELYRIN Inc Competitors
ACELYRIN Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
ACELYRIN Inc
NASDAQ:SLRN
|
229.1m USD | 0 | -0.9 | 0.6 | 0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.3B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.4B USD | 5.2 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
64.8B AUD | 3 | 32.9 | 11 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.4B EUR | 10.3 | 33.2 | 35.8 | 36.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
